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Correlation between class I antigen expression and the ability to generate
tumour infiltrating lymphocytes from bladder tumour biopsies
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Summary Analysis of tissue sections from transurethrally resected bladder tumours using anti-CD3 antibody
showed the presence of T lymphocytes in intra-epithelial layers in eight of 12 cases investigated. In a larger
group of patients, Tumour Infiltrating Lymphocyte (TIL) growth was established from six of 19 cases using
Interleukin-2 (IL-2) and conditioned medium (CM) and resulted in the expansion ofTILs up to 100-fold. TILs
from these individuals were phenotyped with W6/32 (anti-HLA-A,B,C), HB55 (anti-DR) and anti-CD3
antibodies using FAC sorter. The mean±s.d. frequency of positive staining with these antibodies were
96.7±4.0%, 87.5±10.0% and 82.5±7.8% respectively, indicating the activated nature of these T cells. The
cytotoxic activity of these TILs against Daudi (ie, LAK activity) cell line at 25/1 E/T ratios varied from
26.3±3.2 to 62.8±5.2%.
In one case where TILs and autologous tumour cell line were established, cytotoxicity studies showed low
level of cytotoxicity against the autologous tumour cells (15.8±1.6%) compared with 62.8 ± 5.2% against
Daudi. Staining of tumour sections from these 19 individuals with W6/32 and BBM.I revealed positive
staining in six of six that developed TILs but only six of 13 (46%) cases, whose tumour failed to grow TILs
(P<0.02, Fisher exact test).
These results are indicative of the presence of IL-2 passageable T cells in bladder cancer biopsy and
demonstrate that the successful expansion of these cells correlates with the normal expression of class I
antigens on the tumour cells.
Recently there has been speculation from results in vitro
studies that interleukin-2 induced T lymphocyte mediated
tumour rejection response may be the mechanism by which
intravesical BCG produces durable long term disease free
survival in more than 50% of patients with recurrent super-
ficial bladder cancer (Anon, 1991; Ratliff et al., 1991). As a
consequence, there has been increased interest in study of T
lymphocyte activity in bladder tumours since it has long been
known that the extent of lymphocyte infiltration in tumours
is of prognostic significance (Dayan et al., 1964; Pomerance,
1972; Tsujihashi et al., 1989).
Studies of melanoma patients have demonstrated that IL-2
can be used to expand TILs from tumour biopsy (Topalian
et al., 1987) and in nearly half the cases these TILs showed
HLA class I antigen restricted T cell cytotoxicity against the
autologous tumour (Itoh et al., 1988). These cells labelled
with a neomycin resistance gene have been demonstrated in
the circulation for up to 200 days, and at sites where the
tumour underwent rejection, up to 70 days after injection
(Rosenberg et al., 1990). This has provided the most convinc-
ing evidence to date that T lymphocytes can induce tumour
rejection particularly when taken together with the recent
report that the T cell receptor of melanoma TILs show
restricted V alpha gene rearrangements (Nitta et al., 1990)
demonstrating their oligoclonality.
For other adult.solid tumours study of TILs has failed to
demonstrate HLA class I-restricted cytotoxity (CTL). One
possible factor explaining this has come from the recent
studies in bladder cancer. These have demonstrated that
more than 50% of bladder tumours have variable degrees of
polymorphic or monomorphic HLA class I antigen loss
(Nouri et al., 1990) as an immune escape mechanism in
association with P h C G expression (Oliver et al., 1989). This
paper set out to study generation of TILs from bladder
cancer biopsies and investigated the influence of HLA class I
expression on the ability to generate TILs.
Materials and methods
Operative specimens from the Urology Department of the
Royal London Hospital were used immediately after opera-
tion. The tissues were divided into two portions the smaller
of which was snap frozen and kept in liquid nitrogen for
tissue sectioning. The second portion was washed, minced
and the resulting cell suspension and tissue fragments were
used for developing tumour cell lines. Where there were
sufficient cells available, attempts were made to develop TILs
according to the following protocol.
The cell preparation was incubated overnight in RPMI
containing 10% foetal calf serum in the presence or absence
of recombinant IL-2 (100 uml', Biogen). After the incuba-
tion the non-adherent cells were removed, spun down and
resuspended at 0.5 x 106 ml-l in medium containing IL-2 and
cultured in a separate flask. In the cases where single cell
suspension from the 1st passage contained a large amount of
cell debris, density gradient separation was carried out to
remove cell debris. The cells from resulting interface cell ie,
mainly lymphocytes were removed and cultured in medium
with IL-2. TILs from successful cases were fed every 2 or 3
days by adjusting the cell number to 0.5 x 106ml-'. After 2
weeks of culture, CM (5% v/v, see below) was added to the
IL-2 medium in order to increase the rate of cell prolifera-
tion.
The adherent cells were fed until confluence (1 to 2 x 106
25cm2 flask) and were expanded by trypsinising the cells
and sub-culturing into new flasks at a lower density
(0.5 x 10625 cm-2 flask).
Conditioned medium
This was prepared by activating normal peripheral blood
mononuclear cells (prepared from density gradient separated
blood) at 2x 106ml-' with PHA at 2fgml-' for 2h at
37C. The cells were washed three times and resuspended in
medium at 2 x 106 ml-' and culturing continued for a further
36 h. After the incubation cell-free supernatant was removed,
aliquoted and frozen until use.
Cytotoxicity
Established human tumour cell lines Daudi (EBV-transform-
ed B cell line), Molt4 (T cell line), U937 (monocytic like cells)
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and K562 (myelocytic cell) or our own established bladder
cancer cell line (WIL) were labelled with 5"Cr (250pCi/target)
for 1 h at 37C followed by extensive washes. These cells i.e.
target cells (T) were mixed (three replicates/treatment) with
TILs i.e. effector cells (E) to give E/T ratios of 3.2/1, 6.5/1,
12.5/1 and 25/1 in round-bottomed microtitre plates. The cell
mixtures were incubated for different lengths of times, after
which cell-free supernatants were removed and counted using
a gamma counter. The specific killing activity for each treat-
ment was calculated using standard formulae.
Flourescent staining
Cell suspension was prepared in round-bottomed tube to give
0.5 x 106/tube. After centrifugation, supernatant was discard-
ed and cells were resuspended in 50ftl of appropriate anti-
body and incubated for 45 min at room temperature. Cells
were washed in PBS and FITC-conjugated rabbit anti-mouse
i.e. 2nd antibody (1/50 dilution, Dakopatts) was added and
incubation continued for a further 45 min. After three
washes, the cell pellets were used for FACS analysis.
Tissue staining
Frozen sections were cut using a cryostat at a thickness
of 7 Lm, placed on microscope slides, air dried and kept
at -40°C until use. A peroxidase-antiperoxidase staining
method was employed as previously reported by Nouri et al.
(1990).
Monoclonal antibodies
The monoclonal antibodies (Mabs) used as primary reagents
in the form of tissue culture supernatants, together with their
specificities are listed: W6/32 detects all ,2m- associated
HLA-A,B,C antigens (Nouri et al., 1990), BBM.1 detects
,2m (Nouri et al., 1990), HC1O detects non-P2 associated
HLA-A,B,C antigens (Stam et al., 1986), L243 detects HLA-
DR (Lampson et al., 1980), anti-CD3, -CD4 and -CD8
(Ortho-pharmaceutical) detect total T, T helper and T
suppressor/cytotoxic lymphocytes subsets respectively.
Cellproliferation
Proliferation of cells was measured by incorporation of
tritiated thymidine (3H-Tdr, 0.1 ,Ci/well, Amersham) into
cellular DNA. TILs were dispensed into round-bottomed
microtitre plates at 0.5 x 106 well in three replicates and incu-
bated in the presence or the absence of stimulus for 48 h, the
last 4 h of which was in the presence of 3H-Tdr. The degree
of 3H-Tdr uptake by the cells was measured by harvesting the
cells onto filter paper and counting radioactivity in a scintil-
lation counter.
Results
Primary cell culture
The majority of tumour biopsies were not suitable for cultur-
ing either because of their small size or their condition due to
the effects of diathermy. From a total of 19 cases, with
adequate tumour material, six long term passageable TILs
were established.
In an attempt to maximise cell yield, TIL proliferation was
studied with IL-2 alone and IL-2 plus CM results of which
are shown in Figure 1. The addition of CM (5%) to IL-2-
activated cells increased the thymidine incorporation (0.5 x
106 cell/well) from 5,200c.p.m. to 19,800c.p.m. (3.8-fold).
This increase was not due to the carried over PHA which
might have been present in the CM since at 0.1 fg ml-I of
PHA (equivalent to what would have present in 5% CM)
had no stimulatory activity on lymphocytes (data not
shown).
The degree of expansions of two TILs (FB and FS) over a
Figure 1 Proliferative response of TILs from FS to IL-2 (100
uml-') alone (0-0) and IL-2 plus CM (5%, 0-0) for
different cell number per well.
period of 10 days are presented in Figure 2. The cell numbers
doubled every 48 h and case of FB there were approximately
six doublings in 10 days, i.e. 64-fold increase, while for FS
there was approximately 24-fold increase during the same
period.
Cytotoxicity
Cytotoxic activity of TILs from an individuals (FS) against
Daudi cells at varying E/T ratio and different times of incu-
bation are presented in Figure 3. As can be seen, at all the
E/T ratios, the longer the incubation period the greater the
degree of tumour killing. Furthermore, as the ratios of E/T
increased the degree ofcell killing also increased. Thus at 4 h
the specific killing at 3.2/1, 6.5/1, 12.5/1 and 25/1 E/T ratios
were 10.2 ± 1.2, 19.6 ± 3.2, 25.6 ± 6.3 and 34.5 ± 4.2% respec-
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Figure 2 Proliferative response of TILs from FB a, and FS b to
IL-2 and CM (5%) over a period of 10 days.
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Figure 3 Cytotoxic activity of TILs (effector cells, FS) against
Daudi cells (target) at E/T ratios of 25/1 (@--), 12.5/1
(M-U), 6.5/1 (0 0) and 3.2/1 (x-x).
tively 4 h incubation time was chosen and used for subse-
quent experiments.
The ability of cultured TILs (expanded in vitro for more
than 2 weeks) to kill different well established allogeneic
human cells lines was investigated. The results of TIL from
WIL are presented in Figure 4. As expected, there was a
direct correlation between E/T ratios and tumour target kill-
ing. Daudi cells were found to be the most sensitive target
followed by Molt 4, whereas U937 and K562 showed equally
low sensitivity. Thus, the percent specific killing for Daudi
cells at 25/1, 12.5/1, 6.5/1 and 3.2/1 were 62.8 ± 5.2, 59.5 ±
3.2, 44.7 ± 6.2 and 35.2 ± 3.7% respectively. The degree of
specific tumour target killing against Daudi cells by TILs
from FS, JF, FB, AW, LR were 35.5 ± 4.2, 26.3 ± 3.2,
45.4 + 5.9, 33.5 ± 4.8 and 55.5 ± 5.3% respectively. In addi-
tion TILs from WIL (same individual from which permanent
cell line has been established) were found to be capable of
killing autologous tumour cells at 25/1 ratios by 15.8 ± 1.6%
compared with 7.3 ± 1.9% killing of another epithelial cell
line (SKV14, UV-transformed foreskin epithelial line), indi-
cating the low level of specific killing of these cells against
autologous tumour cells.
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TILphenotypes
The presence of T cell markers (CD3, CD4 and CD8) and
HLA class I and II antigens were studied in TILs from six
individuals after being in culture for more than 30 days
(Table I). The percentage of CD3, class I and II positive cells
was greater than 69% for all the six cases. The percent CD8
positive cells was between 29% to 50% (mean 36.3 ± 7.8%),
whereas CD4 positive cells showed greater variability ranging
from 2% to 45% (mean 20.8 ± 16.4%). Furthermore, in all
the cases the percent CD4 positive cells was lower than CD8
positive cells suggesting the preferential expansion of CD8
positive cells.
TILs from WIL frozen after different length of time in
culture were analysed and the results are presented in Table
II. The percentages for CD3 and CD8 positive cells remained
relatively constant throughout the culture period, whereas
CD4 positive cells showed an initial increase followed by
decrease. Thus the percentage of CD4 positive cells at
12.11.88, 1.12.88 and 22.12.88 were 35, 73 and 2% respec-
tively.
Staining of bladder tumour sections of eight of 12 cases
showed the presence of both CD4 and CD8 positive cells
within the tumour epithelium (FS, Figure 5). The discrepancy
between CD3 frequency and combined CD4/CD8 frequency
suggests that an addition population possible of the LAK
lineage was also present.
TIL development and class I antigen expression
Results from staining tumour section with antibodies against
monomorphic class I antigens are presented in Table III. All
of the tumours from which TIL cells developed had normal
expression of monomorphic class I antigen (detected by W6/
32) and P2m (detected by BBM.1) while six of 13 which
failed to develop TILs had diminished expression of the
antigens detected by these antibodies.
Discussion
There are five principal conclusions from this study: (a) T
lymphocytes in bladder tumour biopsy can be expanded in
vitro in response to IL-2; (b) they express phenotypes of
normal activated T cells; (c) they are capable of lysing estab-
lished allogeneic cell lines; (d) TILs from one individual from
whom tumour cell line was established, showed low levels of
specific killing against autologous tumour cells; (e) there was
a correlation between the expression of monomorphic HLA
Table I Cell surface phenotype of TILs from different individuals
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Figure 4 Cytotoxicity activity of TILs (WIL) against Daudi
(X-x), Molt 4 (A-A), U937 (U-*) and K562 (U-M) by
TILs (WIL) at different effector/target ratios.
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45
2
23
4
27
24
50
33
40
30
36
29
87
80
89
87
83
69
Mean
±s.d 96.7±4.0 87.5± 10.0 20.8± 16.4 36.3± 7.8 82.5± 7.3
Percent positive TILs from six individuals using monoclonal
antibodies on cells after 30 days in culture.
Table II TIL (WIL) phenotype after different times ofculture
Date 12/11/88 1/12/88 22/12/88
CD3 76 98 80
CD4 35 75 2
CD8 38 30 33
W6/32 93 nd 98
HB55 70 100 98
Percent positive cells using FACS. nd denotes not done.
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Table III Frequency ofTIL generation and expression ofmonomor-
phic class I antigens
No. ofcases Total no. of Positive staining with:
showing cases studied W6/32 HCJO BBM.J
Positive TIL 6 6 1 6
growth
Negative TIL 13 6 6 6
growth
Staining was assessed by comparing the intensity of antigen expres-
sion between tumour and tumour stroma.
class I antigens detected by W6/32 on tumour and an ability
to generate TILs.
Given the long standing observation that prognosis of
bladder cancer patients correlates with the degree of lympho-
cyte infiltration (Pomerance et at., 1972; Tsujihashi, 1989)
and recent understanding of the effects of IL-2 on lympho-
cyte activation, it is hardly surprising that IL-2 treatment of
bladder tumour biopsies should lead to the clonal expansion
of activated T lymphocytes. This raises the question why
tumour progression occurs despite the presence of lympho-
cytes at the tumour site.
Our studies showed that TILs were only generated from
those tumours with normal HLA class I antigens as measur-
ed by a presence of staining with W6/32 antibody. This may
imply that T cells infiltrate and possibly proliferate .at tumour
sites where there is normal expression of class I antigen
acting as an associative molecules for presentation of puta-
tive neo-antigens. However, 54% of those tumours with
apparently normal class I expression measured by W6/32
failed to develop TILs. The lack of availability of mono-
clonal antibodies against all the polymorphic class I antigens
which are critical for assessing the extent of MHC antigen
abnormality might be one explanation for the observed dis-
crepancy. Other factors including the size or the degree of
lymphocytes infiltration into tumour biospies may also be
important and these are currently under investigation.
The low levels of specific killing of TILs from WIL against
the autologous tumour cells line (15.8 ± 1.6%) is in agree-
ment with the above observation since analysis of MHC class
I antigens on these cells demonstrated that although HLA A
locus antigens A2 and A3 were normally expressed the cells
lacked totally the HLA-B locus antigens B7 and B44 (Nouri
et al., 1991).
It has been disappointing that all of the bladder TILs have
demonstrated non-specific NK/LAK-like activity in contrast
to TILs from melanomas, 30-40% of whlch have demon-
strated class I restricted T- cell mediated CTL. Studies in
animal and in vitro have demonstrated that the levels of class
I antigen expression correlate with the level of specific
cytotoxic T cell killing (Hui et al., 1984) and inversely cor-
relates with NK/LAK killing (Storkus et al., 1987). To date
there have been no reports on such detailed study of poly-
morphic HLA class I expression, on human tumours. It
would be interesting to establish whether the frequency of
loss of polymorphic class I antigens could correlate with the
lack of MHC restricted CTL killing activity in most human
TILs and whether correction of the defect by transfection of
lost antigen led to the development of specific CTL.
In renal cell (Belldegrum et al., 1988) and bladder cancer
(Pape et al., 1979), there are a minority of tumours demons-
trating evidence of possible T cell mediated immune re-
actions. If we are ever to harness the full potential of
immune rejection ofcancer, there is a need to develop techni-
ques to identify the minority of cases with normal HLA
expression using formalin fixed tissue as they may well be the
group who will show maximum benefit from immunological
treatments like IL-2 and BCG.
There has been increasing anecdotal evidence for involve-
ment of papilloma virus in bladder tumour development
(Querci Della Rovere et al., 1988; Bryant et al., 1991).
Preliminary information from our own work has demon-
strated more frequent reactivity of anti-HPV16 E7 antibody
with superficial than invasive tumour (Oliver, 1989). As loss
of HLA class I is also more frequent in invasive tumours
(Nouri et al., 1990), it is possible that HPV antigen in
association with appropriate HLA could be explored as pos-
sible vaccine for cancer patients (Anon, 1989).
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